Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reduced-intensity, Partially HLA Mismatched, Related-donor Allogeneic BMT With Fludarabine, Busulfan, and High-dose Posttransplantation Cyclophosphamide for Hematologic Malignancies.

Next Previous
Trial Profile

Reduced-intensity, Partially HLA Mismatched, Related-donor Allogeneic BMT With Fludarabine, Busulfan, and High-dose Posttransplantation Cyclophosphamide for Hematologic Malignancies.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tacrolimus (Primary) ; Busulfan; Cyclophosphamide; Fludarabine
  • Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; B-cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Graft-versus-host disease; Hairy cell leukaemia; Hodgkin's disease; Leukaemia; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Myeloid leukaemia; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use

Most Recent Events

  • 03 Jul 2018 Biomarkers information updated
  • 05 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 01 Sep 2010 Actual initiation date added to 1 Aug 2010 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top